⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Atorvastatin
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-01 — Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.: cross-connection with rapamycin-mtor: Both are candidate interventions for atherosclerotic aging but act on different axes — statins on LDL/plaque lipids, rapamycin on plaque macrophage content and lymphoid regulatory remodeling — inviting comparison or combination framing in aged-CVD models. (novelty: 3)
- 2026-08-10 — Chronic subdural hematoma through the hallmarks of aging: a geroscience framework for the commonest neurosurgical condition of older adults.: CSDH geroscience minireview cites the ATOCH randomized trial of atorvastatin in chronic subdural hematoma as proof-of-concept that mechanism-directed medical therapy can modify a canonical geriatric neurosurgical disease, framing atorvastatin alongside emerging gerotherapeutics (e.g. senolytics) rather than reporting new primary data. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
Chronic subdural hematoma through the hallmarks of aging: a geroscience framework for the commonest neurosurgical condition of older adults.
10-aug-2026
novelty 3
per-area 3
strengthens